Periextubation caffeine in preterm neonates: a randomized dose response trial.

Area of Science:

• Neonatalogy
• Pharmacology
• Clinical Trials

Background:

• Preterm infants often experience apnea of prematurity, increasing risks during extubation.
• Caffeine citrate is commonly used to manage apnea in neonates.
• Optimal dosing for periextubation management in preterm infants remains unclear.

Purpose of the Study:

• To compare the efficacy of three caffeine citrate dosing regimens (3, 15, and 30 mg/kg) for ventilated preterm infants during the periextubation period.
• To evaluate the impact of different caffeine doses on extubation success and related physiological parameters.

Main Methods:

• A randomized double-blind clinical trial involving 127 preterm infants (<32 weeks gestation) requiring ventilation.
• Caffeine citrate was administered daily for 6 days, starting 24 hours before planned extubation or within 6 hours of unplanned extubation.
• Primary outcome was extubation failure; secondary outcomes included apnea incidence and continuous cardiorespiratory monitoring in a subgroup.

Main Results:

• No significant difference in extubation failure rates was observed between the 3, 15, and 30 mg/kg caffeine groups.
• Infants receiving higher caffeine doses (15 and 30 mg/kg) experienced significantly less documented apnea compared to the 3 mg/kg group.
• A subgroup analysis showed higher doses correlated with increased heart rate, improved oxygen saturation, and less time with saturation <85%.

Conclusions:

• Higher doses of caffeine citrate offer short-term benefits by reducing apnea in ventilated preterm infants during the periextubation phase.
• Further research with larger cohorts is needed to ascertain the optimal caffeine dosing strategy and long-term outcomes for preterm infants.